FMP

FMP

Enter

ONC.TO - Oncolytics Biotech Inc.

Profile of Oncolytics Biotech Inc.(ONC.TO), Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and

About

ceo

Dr. Matthew C. Coffey M.B.A., Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.oncolyticsbiotech.com

exchange

TSX

Description

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

CIK

N/A

ISIN

CA6823108759

CUSIP

N/A

Address

322 11th Avenue SW

Phone

14036707380

Country

CA

Employee

29

IPO Date

Jun 1, 2000

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep